Management of advanced Parkinson's disease in Israel: Clinicians viewpoint and action items.

Parkinson's disease (PD) is taking a staggering toll on healthcare systems worldwide, with the bulk of the expenditures invested in the late stages of the disease. Considering the rising life expectancy and the increasing prevalence of PD across the globe, a clear understanding of the early signs and treatment options available for advanced PD (APD), will facilitate tailoring management programs and support services. This task is complicated by the lack of both global consensus in defining APD and standardized care guidelines. This perspective prepared by a panel of movement disorder specialists, proposes to extend and optimize currently accepted PD coding to better reflect the diverse disease manifestations, with emphasis on non-motor features. The panel seeks to promote timely diagnosis by adjustment of evaluation tools for use by community neurologists and suggests modification of eligibility criteria for advanced therapy. Moreover, it advocates multidisciplinary assessments of APD patients to drive personalized, patient-centered and holistic management. Overall, earlier and more targeted intervention is expected to markedly improve patient quality of life.

Informations de copyright

Copyright © 2022 Gurevich, Arkadir, Badarny, Benizri, Cohen, Djaldetti, Hassin-Baer, Kestenbaum, Nitsan, Zlotnik and Yahalom.

Déclaration de conflit d'intérêts

Author TG was member of the advisory board on Advanced Parkinson’s disease 23.07.2020 supported by Abbvie, consultant and/or scientific advisor/lecturer for Neuroderm, AbbVie, Cytora, Allergan, Teva, and Medison, and received research support from Parkinson’s Foundation and Israel Innovation Authority. Author SH-B had received funding for research from Abbvie and speaker honoraria from Abbvie, Medison, and Allergan, consultancy fees from Neuroderm, Abbvie, and Takeda and Teva, and advisory fees from Teva and Abbvie. Author MK was consultant and lecturer for Teva, Medison, and Abbvie. Author ZN participated in advisory boards, received speaker fees from Abbvie and Teva, and had received educational travel bursaries from Abbvie and Teva. Author YZ participated in advisory boards, received speaker fees from Abbvie, Medison, and Teva, and had received educational travel bursaries from Abbvie and Teva. Author GY was consultant for Abbvie and Takeda. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.